Europe's new paediatric rules bear fruit
This article was originally published in Scrip
The EU's drive to encourage the development of drugs for children has finally borne fruit in the form of a paediatric version of Merck Sharp & Dohme's Cancidas for use in fungal infections. This is a small, but very welcome, first step towards ensuring that children have a full range of medicines at their disposal and are not treated like "small adults".
You may also be interested in...
The US company is bringing extra supplies of lopinavir/ritonavir into France but stresses that the combination treatment is not authorized for treating patients with the coronavirus.
As part of its efforts to preserve patient access to medicines amid the COVID-19 pandemic, Russia is planning to cap drug prices if increases of more than 30% are detected. It will also allow online sales of non-prescription drugs and may also tighten the rules on fake and substandard products.
France is exploring the use of hydroxychloroquine and lopinavir/ritonavir in COVID-19, but only in hospitalized patients and in clinical trials, and has banned all exports of the products to avoid possible shortages.